Open-market purchases of Artiva Biotherapeutics, Inc. (ARTV) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Jul 24, 2026 | RA Capital Management, L.P. / Peter KolchinskyDirector / 10% Owner | $2.58M | Added | |||
| 3-day cluster buy: 120,582 shares @ $9.55 avg (Jul 21, range $9.16–$10.00), 84,124 @ $9.93 avg (Jul 22, range $9.72–$10.00), 59,880 @ $9.96 avg (Jul 23, range $9.40–$10.00). Weighted avg buy price ~$9.76; current spot $10.13 (+3.8%). RA Capital adds to existing ~17.2M-share position; co-filers include Rajeev Shah (Director). Consistent accumulation capped at $10 round-number level across all three sessions. | ||||||
| Jun 22, 2026 | RA Capital Healthcare Fund, L.P.10% Owner | $4.60M | Added | |||
| 531,326 shares at ~$8.65 avg across Jun 12–16; stock +13.5% to $9.82 since purchase | ||||||
| Jun 15, 2026 | RA Capital Management10% Owner / Director | $7.65M | Added | |||
| Three-day cluster buy: 479,039 shares at $6.91 (June 9), 103 shares at $7.00 (June 10), 548,580 shares at $7.91 (June 11). Weighted avg $7.45. RA Capital already holds 33.7% of ARTV after $100M+ in prior open-market accumulation. CAR-NK cell therapy conviction play. | ||||||
| Jun 12, 2026 | Peter Kolchinsky / RA Capital Management L.P.Director / 10% Owner | $4.34M | Added | |||
| Weighted avg $7.91/share (range $7.605–$8.00); final leg of 3-day cluster buy (June 9–11) totalling ~$7.65M. RA Capital holds 33.7% stake. Current price $8.00 (+1.1% vs buy). NK-cell therapy biotech. | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.